BLR-200 / BLR Bio - LARVOL DELTA

Rosalind Franklin University Helix 51 Incubator Company BLR Bio Presents Promising New Scleroderma Drug Data at International Rheumatology Meeting (Yahoo Finance) - "BLR Bio's newly presented data serves to further elucidate both the mechanism of action and efficacy of BLR-200 in a bleomycin-induced in vivo model of systemic sclerosis...BLR-200 effectively eliminated this cell population, with a corresponding absence of skin thickening and fibrosis in the treated preclinical models....BLR Bio also presented data on its research on CCN proteins — signaling modulators in development, wound healing, and tissue repair — as potential non-invasive biomarkers for systemic sclerosis. The studies revealed distinct serum patterns of CCN3 and CCN2 between early versus late-stage patients and healthy controls. Notably, CCN3 alone showed promise as a biomarker to differentiate scleroderma patients from healthy individuals."

Preclinical • Systemic Sclerosis

Rosalind Franklin University Incubator Company Announces Positive Anti-Fibrotic Effects in Lung Fibrosis Model (PRNewswire) - "BLR Bio...announced new data on its novel therapy for systemic sclerosis and lung fibrosis at the British Society for Rheumatology (BSR) Annual Conference this week in Manchester, UK....In the new study, presented by Dr. Andrew Leask at the University of Saskatchewan in Canada, BLR 200, the company's lead compound, demonstrated the ability to reduce key disease tissue markers for fibrotic lung disease. Reductions were shown in Ashcroft scores, collagen levels, and both fibronectin-1 (FN-1) and profibrotic CCN4, signaling molecules involved in the development of scar tissue. Dr. Leask is a leading expert in fibrosis and CCN proteins and a long-term collaborator with BLR Bio."

Preclinical • Fibrosis • Immunology • Systemic Sclerosis

Rosalind Franklin University Helix 51 Incubator Company Granted FDA Orphan Drug Designation for Treatment of Scleroderma (PRNewswire) - "BLR Bio...announced that the U.S. Food and Drug Administration (FDA) granted an Orphan Drug Designation for its investigational therapy BLR-200 for the treatment of systemic sclerosis (SSc), also known as scleroderma....BLR-200 is different from other therapies now in development for the treatment of systemic sclerosis."

Orphan drug • Immunology • Scleroderma • Systemic Sclerosis